Show simple item record

dc.contributor.advisorŞimşek, Hasan Bolkan
dc.contributor.authorKesimer, Mehmet
dc.date.accessioned2020-12-29T08:22:41Z
dc.date.available2020-12-29T08:22:41Z
dc.date.submitted1991
dc.date.issued2018-08-06
dc.identifier.urihttps://acikbilim.yok.gov.tr/handle/20.500.12812/361809
dc.description.abstract?76- VI. ÖZET Yaşları 31 ve 65 arasında olan ve gerek öykü gerek semptom ve gerekse EK6 delillerine dayanarak, atherosklerotik kalp hastalığı teşhisi konmuş 52 hastada total kolesterol, HDL kolesterol ve trigliserid tayinleri 43 hastada ise apolipoprotein A-l ve apolipoprotein B ölçümleri yapılmış, ldl ve VLDL kolesterol değerleri friedewald formülüne uygun olarak hesaplanmıştır. Bu hasta grubu, KKH hikayesi göstermeyen 27 sağlıklı kişiden oluşan kontrol grubuyla kıyaslanmıştır. İstatistiksel değerlendirmede atherosklerotik kalp hastalarının; total kolesterol (x = 233,2 mg/dl ), LDL kolesterol (x = 156,9 mg/dl ) Apolipoprotein B (x = 100,5 mg/dl ) Total /HDL kolesterol (x = 6,4 ) LDL /HDL kolesterol (x = 4,2 ) değerleri kontrol grubundan (Total kolesterol (x) = 189, LDL kolesterol = 113,3 Apolipoprotein B= 83,8 mg/dl, Total /HDL kolesterol = 3,7, LDL/HDL kolesterol=2,2) anlamlı derecede yüksek (P < 0,001), VLDL kolesterol (x=37,5 mg/dl) ve trigliserid (x = 186,6 mg/dl) değerleri de kontrol grubundan (VLDL (x) = 25,4, trigliserid 127,2 mg/dl) anlamlı derecede yüksek (P < 0, ol), HDL kolesterol (x = 38,1 mg/dl), Apolipoprotein A-l (x = 107,1 mg/dl), Apo A-l/Apo B değerleri ise kontrol grubundan anlamlı derecede düşük (P<0,ool) bulunmuştur. sonuçlar literatür bilgilerinin ışığı altında, özellikle son yıllarda önem kazanan, apolipoproteinlerin-77- atheroskleroz bağlantısı yönünden tartışılmıştır. Buna göre Apo A-l ve Apo B'nin KKH için, total kolesterol, HDL ve LDL kolesterol kadar iyi bir gösterge olduğunu, Apo A-I/Apo B oranının ise KKH için tüm serum lipidleri ve lipoproteinlerinden daha iyi bir gösterge olabileceği kanısına varılmıştır.
dc.description.abstract?78- VII. SUMMARY Atherosclerotic heart disease is diagnosed on patients whose ages are between 31 and 65, depending on their symptoms and EGG evidence. Total cholesterol, HDL cholesterol and triglicerides on 52 patient were studied. Determination of apolipoprotein A-l and apolipoprotein B were studied on 43 patient. LDL and VLDL-cholesterol was calculated according to the Friedewald formula. These patient group was compared with the control group that consist of 27 healthy person who had no story of coronary heart disease. In statistical evaluation, total cholesterol (x= 233,2 mg/dl), LDL cholesterol (x= 156,9 mg/dl), Apolipoprotein £B Cx> 100,5 mg/dl), Total/HDL cholesterol (x = 6,4), LDL/HDL cholesterol (x = 4,2) value of atherosclerotic heart patient are significantly higher (P < 0,001) than control group (Total cholesterol (x) = 189, LDL cholesterol=H3,3, Apolipoprotein B= 83,8 mg/dl, Total/HDL cholesterol=3,7, ldl/hdl cholesterol=2,2), VLDL cholesterol (x= 37,5 mg/dl) and triglicerides (x = 186,6 mg/dl) value of patient group are significantly higher than control group (VLDL cholesterol (x) = 25,4, trigliserides = 127,2 mg/dl). The patient group had significantly lower HDL cholesterol (x = 38,1 mg/dl) Apo A-l (x = 107,1 mg/dl) and Apo A-l/Apo B (x = 1,07) value than control group (HDL cholesterol (x)= 50,8, Apo A-l = 132,9 mg/dl, Apo A-l/Apo B = 1,58).-79- The results were discussed in view of literatures knowledge especially in respect of apo A-l, Apo B and atherosclerosis relationship. ît was realized that apo A-l and Apo B is as good discriminator as total cholesterol, LDL and HDL cholesterol and Apo A-l /apo B ratio is a better discriminator than all serum lipids and lipoproteins for CHD.en_US
dc.languageTurkish
dc.language.isotr
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.rightsAttribution 4.0 United Statestr_TR
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectBiyokimyatr_TR
dc.subjectBiochemistryen_US
dc.titleKoroner atheroskleroz hastalarında serum apolipoprotein A-I, apolipoprotein B ve lipid parametrelerinin değerlendirilmesi
dc.typemasterThesis
dc.date.updated2018-08-06
dc.contributor.departmentDiğer
dc.subject.ytmApolipoproteins B
dc.subject.ytmCoronary artery disease
dc.subject.ytmApolipoprotein A I
dc.subject.ytmLipids
dc.identifier.yokid19148
dc.publisher.instituteSağlık Bilimleri Enstitüsü
dc.publisher.universityGAZİ ÜNİVERSİTESİ
dc.identifier.thesisid19148
dc.description.pages104
dc.publisher.disciplineDiğer


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/embargoedAccess
Except where otherwise noted, this item's license is described as info:eu-repo/semantics/embargoedAccess